Clinical TrialJul 13, 2026, 07:31 AM
Cognition Therapeutics CEO to Discuss START Study, Phase 3 DLB Trial
AI Summary
Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the event, Ms. Ricciardi will provide updates on the company's ongoing START study and discuss the planned initiation of a Phase 3 registrational study for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis. Zervimesine is an investigational once-daily oral therapy that has shown promise in Phase 2 trials.
Key Highlights
- CEO Lisa Ricciardi to participate in B. Riley Mind, Muscle & Vision Summit on July 16, 2026.
- Discussion will cover the status of the ongoing START study (Phase 2 for MCI and early Alzheimer's).
- Planned initiation of a Phase 3 registrational study for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.
- Zervimesine (CT1812) is an investigational once-daily oral therapy.
- Company is backed by nearly $200 million in National Institutes of Health and related foundation grants.
Price Impact
More from CGTX